Category: News
BERGENBIO TO PRESENT UPDATES FROM ONGOING PHASE II BEMCENTINIB COMBINATION STUDY IN REFRACTORY NSCLC AT WCLC 2020
· Bemcentinib in combination with pembrolizumab was well-tolerated and showed promising clinical activity in refractory…
Read MoreBERGENBIO PRESENTING AT VIRTUAL INVESTOR CONFERENCES
Bergen, Norway, 12 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreDATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF BERGENBIO’S BGBC020 TRIAL ASSESSING BEMCENTINIB IN COVID-19 PATIENTS
Bergen, Norway, 11 January 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO CONFIRMS FIRST COVID-19 PATIENT ENROLLED WITH BEMCENTINIB IN ACCORD TRIAL
Bergen, Norway, 8 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO PRESENTS UPDATED CLINICAL DATA FROM TWO PHASE II STUDIES OF BEMCENTINIB IN AML AND MDS PATIENTS AT ASH 2020
Bergen, Norway, 6 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBERGENBIO TO PRESENT AT UPCOMING HEALTHCARE CONFERENCES IN DECEMBER 2020
Bergen, Norway, 3 December 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159